Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathwaysSimon J. Allison, Roger M. Phillips|Oncogenesis|2014Cited by 142
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligandsSimon J. Allison, Roger M. Phillips|Cancer Letters|2017Cited by 67
Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitorsMaryam Ahmadi, Roger M. Phillips|British Journal of Pharmacology|2013Cited by 33